Aptinyx (NASDAQ:APTX – Get Rating) released its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02, Fidelity Earnings reports. During the same quarter in the prior year, the firm posted ($0.22) EPS.
Shares of APTX opened at $0.70 on Friday. The company’s fifty day moving average is $1.78 and its 200 day moving average is $2.43. Aptinyx has a fifty-two week low of $0.57 and a fifty-two week high of $4.73. The stock has a market capitalization of $47.40 million, a PE ratio of -0.59 and a beta of 1.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 20.18 and a current ratio of 20.18.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its stake in Aptinyx by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 123,937 shares of the company’s stock worth $331,000 after buying an additional 6,133 shares during the period. Royal Bank of Canada boosted its stake in Aptinyx by 244.5% during the second quarter. Royal Bank of Canada now owns 9,288 shares of the company’s stock worth $26,000 after buying an additional 6,592 shares during the period. Charles Schwab Investment Management Inc. purchased a new position in Aptinyx during the fourth quarter worth $54,000. BlackRock Inc. boosted its stake in Aptinyx by 1.5% during the fourth quarter. BlackRock Inc. now owns 1,374,768 shares of the company’s stock worth $3,669,000 after buying an additional 20,928 shares during the period. Finally, Cetera Advisor Networks LLC purchased a new position in Aptinyx during the first quarter worth $92,000. Institutional investors own 55.97% of the company’s stock.
About Aptinyx (Get Rating)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.
- Get a free copy of the StockNews.com research report on Aptinyx (APTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.